AC137 amylin mimic data

AMLN presented data gathered in a Phase II pharmacokinetic study of the amylin mimic AC137 showing an unexpected dampening of glucose blood levels in diabetics after meals. AMLN found that the agent can limit the rise of blood glucose after a standard breakfast. Normal subjects experience a rise of blood glucose from about 5mmol. to 7mmol. whereas post-meal readings from diabetics typically reach 10mmol. "AC137 can limit the rise to 7 or 8mmol. in diabetics," said Timothy Rink, AMLN president. "The dampening effect of AC137 on glucose was statistically significant, and appears to be dose-dependent," Rink added.

Complete data on the glucose-smoothing effect, collected from the ongoing Phase II trial in 24 patients, will be presented by the first quarter of next year. Also, the effect now will be examined in ongoing trials, and a new trial designed to look at the effect specifically is being planned and will be initiated in the next few months, Rink said. ...